An obvious problem for the surgeon or oncologist treating breast cancer has been to identify
the patients likely to respond to endocrine manipulation. Until recently, clinical factors such …

A consensus-development meeting on" Steroid Receptors in Breast Cancer" was held at the
National Institutes of Health on June 27–29. The purpose of this meeting, which was …

Publisher Summary This chapter discusses the endocrine therapy and the use of steroid
receptors in human breast cancer. The chapter highlights the information that estrogen …

Estrogen and progesterone receptors (ER and PR) have now been studied in clinical breast
cancer for more than 20 years. Positive receptor status correlates with favorable prognostic …

In estrogen target tissues and hormone‐dependent tumors, the steroid enters the cells and
binds to a cytoplasmic protein called the estrogen receptor (ER). The steroid‐receptor …

The measurement of cytoplasmic estrogen receptor in tumors from patients with breast
cancer is now well established. Potential uses include prognosis of early recurrence …

The identification of steroid receptors in human breast cancer tissues has provided
biochemical markers to predict hormone responsiveness. Analysis of tumors from 328 …

The estrogen receptor (ER) assay has become a standard practice in the management of
advanced breast cancer. Tumors lacking ER respond infrequently to endocrine therapy …

Breast cancer is often hormone responsive, since growth or regression of tumors can often
be modulated by appropriate endocrine manipulations. Estrogen and progesterone appear …

Our present state of knowledge regarding estrogen and progesterone receptors (ER and
PgR) has led to changes in. treatment strategies: patients without receptors in their tumor …